EUCTR2006-004455-37-DE
Active, not recruiting
Not Applicable
Effects of a Pioglitazone/ Metformin Fixed Combination in Comparison to Metformin in Combination with Glimepiride on Diabetic Dyslipidemia
Takeda Pharma GmbH0 sites260 target enrollmentApril 23, 2007
ConditionsPatients with Type 2 Diabetes mellitus (HbA1c > 6.5% and >/ = 9%) and diabetic dylipidemia inefficiently treated with Metformin monotherapy (maximal individually tolerated dose) will be eligible for this trial.MedDRA version: 8.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate control
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Patients with Type 2 Diabetes mellitus (HbA1c > 6.5% and >/ = 9%) and diabetic dylipidemia inefficiently treated with Metformin monotherapy (maximal individually tolerated dose) will be eligible for this trial.
- Sponsor
- Takeda Pharma GmbH
- Enrollment
- 260
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with type 2 diabetes mellitus, HbA1c \> 6\.5% and Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •Type 1 diabetes mellitus, progressive fatal disease, history of significant cardiovascular (NYHA I\-IV), respiratory, gastrointestinal, hepatic, renal, neurological, psychatric and/ or hematological disease, history of macular oedema, change in dosage of statin treatment, change in dosage of anticoagulant treatment, start of statin and/ or anticoagulant treatment during study participation, sexually active women not consistenly or correctly practicing birth control, lack of compliance
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Effect of pioglitazone and metformin in combination with insulin therapy in patients with type 2 diabetesType 2 diabetesJPRN-UMIN000003830Chigasaki Municipal Hospital250
Active, not recruiting
Not Applicable
Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study - PIOcomb StudyEUCTR2007-006706-14-ATTakeda Pharma GmbH200
Active, not recruiting
Not Applicable
Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study - PIOcomb StudyDiabetes mellitus type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2007-006706-14-DETakeda Pharma GmbH
Completed
Not Applicable
Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetestype 2 diabetesJPRN-UMIN000001891Jikei University School of Medicine20
Completed
Not Applicable
Differential effects of metformin and pioglithazone on hs-CRP in patients with type II DM.diabetes mellitus II.non-insulin-dependent diabetes mellitusIRCT201109067482N1Qazvin University of Medical Sciences40